Replies to post #5093 on Regen BioPharma Inc (RGBP)

[mrMando]

DcellVax is such an amazing out-side-the-box gene silencing method. There is nothing like it yet. That is why they have filed for patent. If successful, there will be an opportunity to own the technology and license it out. This greatly increases the value of the therapy cancer vaccine.

Regen BioPharma Files Patent Application on New Therapy That Uses the "Innate" Immune System to Kill Cancer
11:44a ET September 16, 2014 (Market Wire)

Regen BioPharma Inc. (OTCBB: RGBP) announced today filing of a patent application covering novel means of stimulating the "innate" immune system to kill cancer. The patent discloses specific siRNA molecules that were discovered by Regen BioPharma during the preclinical development of dCellVax. Preliminary data generated by the Company suggests that the new approach appears effective against various human cancers including lung, skin, glioma, and breast cancer

Here are pieces of the IND PR for DcellVax explaining it's uniqueness.

"The dCellVax approach to cancer is different than other gene silencing therapeutics currently in development.

Most companies use gene silencing to block abnormal genes found in the tumor (oncogenes). Unfortunately, to get tumor cure with this approach, one would need to silence 100% of the cancer cells, otherwise, the remaining cells will continue to multiply. Achieving silencing in 100% of cancer cells is next to impossible.

With the dCellVax approach, we are silencing genes that suppress the immune response to cancer. With this approach, even achieving silencing in 20% of immune cells is enough to cause an increased immune response, which hopefully will overcome the tumor," said Dr. Ichim. "To our knowledge this is the first time that gene silencing is being proposed as a means of overcoming immune suppression in a clinical situation."